We are live on ! Find out more
IBB icon

iShares Biotechnology ETF

399 hedge funds and large institutions have $6.62B invested in iShares Biotechnology ETF in 2015 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 144 increasing their positions, 113 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 37

32% more funds holding in top 10

Funds holding in top 10: 2533 (+8)

27% more repeat investments, than reductions

Existing positions increased: 144 | Existing positions reduced: 113

26% more capital invested

Capital invested by funds: $5.23B → $6.62B (+$1.38B)

8% more funds holding

Funds holding: 369399 (+30)

56% less call options, than puts

Call options by funds: $479M | Put options by funds: $1.09B

Holders
399
Holders Change
+30
Holders Change %
+8.13%
% of All Funds
10.63%
Holding in Top 10
33
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+32%
% of All Funds
0.88%
New
70
Increased
144
Reduced
113
Closed
37
Calls
$479M
Puts
$1.09B
Net Calls
-$610M
Net Calls Change
-$237M
Name Holding Trade Value Shares
Change
Change in
Stake
TM
201
Thiel Macro
California
$993K +$956K +8,670 New
EFS
202
Essex Financial Services
Connecticut
$990K +$134K +1,215 +16%
ACS
203
Archford Capital Strategies
Illinois
$982K -$173K -1,566 -15%
NCM
204
Noesis Capital Mangement
Florida
$950K -$468K -4,245 -34%
PP
205
Paloma Partners
Connecticut
$948K -$18.1M -164,217 -95%
MWP
206
MYCIO Wealth Partners
Pennsylvania
$947K
PFM
207
Parsec Financial Management
North Carolina
$944K +$194K +1,755 +27%
NCM
208
Neumann Capital Management
California
$928K
ST
209
Semper Trust
Pennsylvania
$919K
HDIM
210
Hanson & Doremus Investment Management
Vermont
$907K -$13.2K -120 -1%
TCM
211
Traynor Capital Management
Pennsylvania
$845K +$60.2K +546 +8%
IAA
212
Ironsides Asset Advisors
North Carolina
$844K +$506K +4,584 +164%
SIA
213
Starfire Investment Advisers
Michigan
$790K +$761K +6,900 New
BCM
214
Bienville Capital Management
New York
$776K +$140K +1,272 +23%
WHI
215
William Harris Investors
Illinois
$773K
RCG
216
Ruggie Capital Group
Florida
$759K -$581K -5,265 -44%
GT
217
Glenmede Trust
Pennsylvania
$749K +$58.6K +531 +9%
FVCM
218
F&V Capital Management
Florida
$735K
SI
219
SII Investments
Wisconsin
$726K +$18.5K +168 +3%
PTC
220
Private Trust Company
Ohio
$719K -$10.3K -93 -1%
AW
221
ACG Wealth
Georgia
$718K -$4.96K -45 -0.7%
EA
222
Elm Advisors
California
$714K
WS
223
Wedbush Securities
California
$697K +$123K +1,113 +22%
MGIA
224
Moneta Group Investment Advisors
Missouri
$687K
DAS
225
Dynamic Advisor Solutions
Arizona
$679K +$18.9K +171 +3%

IBB Hedge Fund Activity: Q1 2015 in Review

399 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2015, worth a combined $6.62B — up 26% from $5.23B a quarter earlier.

Buyers outnumbered sellers: 70 funds opened new IBB positions and 37 closed out — a net gain of 33 holders — while 144 added to existing stakes and 113 trimmed.

The largest buyer was BNP Paribas Financial Markets, adding an estimated $563M. The largest seller was Deutsche Bank, exiting entirely with an estimated $467M sold.

  • 399 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2015, up from 369 in Q4 2014.
  • Funds reported $6.62B of iShares Biotechnology ETF stock for Q1 2015, up 26% quarter-over-quarter.
  • 70 funds opened new iShares Biotechnology ETF positions in Q1 2015 and 37 closed out, a net change of +33 holders.
  • The largest iShares Biotechnology ETF buyer in Q1 2015 was BNP Paribas Financial Markets, an estimated $563M added.
  • The largest iShares Biotechnology ETF seller in Q1 2015 was Deutsche Bank, an estimated $467M sold.

Based on aggregated 13F filings for Q1 2015.